Drimva

Legend Biotech

VP, Head of Preclinical Development

$294K–$387K

Somerset, New Jersey, United States · Director · Full-time · Posted Jul 21, 2026

Experience
Minimum 15 years of progressive preclinical drug development experience, including at least 5 years in a senior leadership role with direct accountability for IND-enabling programs.
Education
PhD in pharmacology, toxicology, immunology, cell biology, or a closely related discipline.
Visa sponsorship
Applicants must be authorized to work in the United States; employment eligibility is verified through E-Verify.

About the job

Leads global preclinical development across the company’s pipeline, from candidate nomination through IND-enabling studies, and builds the team responsible for pharmacology and toxicology.

What you'll do

  • Set preclinical strategy and scientific standards; integrate PK, PD, safety, and biodistribution data to inform clinical development and regulatory submissions.
  • Lead preclinical development for cell and gene therapy modalities and own the nonclinical component of IND applications.
  • Build and develop the preclinical team, oversee CRO relationships, and provide preclinical risk assessments for portfolio decisions.

What they ask for

  • PhD in pharmacology, toxicology, immunology, cell biology, or a closely related discipline.
  • At least 15 years of progressive preclinical drug development experience, including at least 5 years in senior leadership with direct accountability for IND-enabling programs.
  • Expertise in at least two of in vitro pharmacology, in vivo pharmacology, and toxicology, with working knowledge of the third; experience designing and overseeing GLP toxicology studies.
  • Experience in cell therapy, gene therapy, or advanced therapy development; successful IND submissions with accountability for nonclinical pharmacology and toxicology sections.

Pay

$294,483 — $386,511 USD (base salary)

Tools

CAR-T, lentiviral vector-based in vivo CAR-T, GLP, PK, PD, CRO, IND

Model-written summary · the original posting is authoritative

First seen Oct 29, 2026 · Last verified Nov 6, 2026 (UTC)